Back to Search
Study ID

LPT109096

Clinical Study ID

LPT109096

Study Title Phase II Randomized Trial of Neoadjuvant Trastuzumab and/or Lapatinib plus Chemotherapy (Sequential FEC75 and Paclitaxel) in Women with ErbB2- (HER2/neu-) Overexpressing Invasive Breast Cancer
Clinicaltrials.gov Identifier NCT00524303
Sponsor This product has been transferred to Novartis. GSK Clinical Study Register is no longer maintained for this study. The most up to date information is available on clinicaltrials.gov.
Collaborators N/A
Phase phase 2
Study Recruitment Status Product Sponsorship Transferred to Novartis
Generic Name lapatinib
Trade Name Tykerb,Tycerb,Tyverb; Tyverb,Tykerb,Tycerb
Study Indication Neoplasms, Breast

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.